{{Rsnum
|rsid=737267
|Gene=SLC2A9
|Chromosome=4
|position=9933120
|Orientation=plus
|GMAF=0.2557
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=SLC2A9
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 52.7 | 41.1 | 6.2
| HCB | 99.3 | 0.7 | 0.0
| JPT | 97.3 | 2.7 | 0.0
| YRI | 22.4 | 51.7 | 25.9
| ASW | 26.3 | 54.4 | 19.3
| CHB | 99.3 | 0.7 | 0.0
| CHD | 91.7 | 8.3 | 0.0
| GIH | 61.4 | 34.7 | 4.0
| LWK | 21.8 | 58.2 | 20.0
| MEX | 44.8 | 41.4 | 13.8
| MKK | 34.0 | 56.4 | 9.6
| TSI | 52.0 | 43.1 | 4.9
| HapMapRevision=28
}}{{GWAS Summary
|SNP=rs737267
|PubMedID=18327257
|Condition=Serum urate
|Gene=SLC2A9
|Risk Allele=C
|pValue=3.00E-009
|OR=0.88
|95CI=NR) uM decrease in uric acid (females only
}}

{{omim
|desc=HYPOURICEMIA, RENAL, 2; RHUC2
|id=612076
|rsnum=737267
}}

{{omim
|id=606142
|desc=SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER
|rsnum=737267
}}

{{PharmGKB
|RSID=rs737267
|Name_s=
|Gene_s=SLC2A9
|Feature=
|Evidence=PubMed ID:18327257; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS Results: SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout (Initial Sample Size: 794 individuals; Replication Sample Size: 706 individuals; Risk Allele: rs737267-C).
|Drugs=
|Drug Classes=
|Diseases=Cardiovascular Diseases
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA162356759
}}

{{PMID Auto
|PMID=20589538
|Title=Variation in the Uric Acid Transporter Gene SLC2A9 and Its Association with AAO of Parkinson's Disease
}}

DeCode reports that the [[rs737267(G;T)]] genotype is associated with 0.77 times the normal risk of [[gout]], and the [[rs737267(G;G)]] genotype is associated with 1.25 times higher risk of [[gout]]. {{PMID|18398472|OA=1
}}

{{omim
|id=606142
|rsnum=737267
|variant=0003
}}

{{PMID Auto
|PMID=17997608
|Title=The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts.
|OA=1
}}

{{PMID Auto
|PMID=18606621
|Title=SLC2A9--a fructose transporter identified as a novel uric acid transporter.
|OA=1
}}

{{PMID Auto
|PMID=19260141
|Title=Genome-wide association study of biochemical traits in Korcula Island, Croatia.
|OA=1
}}

{{PMID Auto
|PMID=20162744
|Title=Interactions between genetic variants in glucose transporter type 9 (SLC2A9) and dietary habits in serum uric acid regulation.
|OA=1
}}

{{PMID Auto
|PMID=20162745
|Title=Association of nephrolithiasis and gene for glucose transporter type 9 (SLC2A9): study of 145 patients.
|OA=1
}}

{{PMID Auto
|PMID=20348110
|Title=Bayesian methods for instrumental variable analysis with genetic instruments ('Mendelian randomization'): example with urate transporter SLC2A9 as an instrumental variable for effect of urate levels on metabolic syndrome.
|OA=1
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs737267
|overall_frequency_n=42
|overall_frequency_d=128
|overall_frequency=0.328125
|n_genomes=36
|n_genomes_annotated=0
|n_haplomes=42
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{PMID Auto
|PMID=23272134
|Title=Changes in uric acid levels following bariatric surgery are not associated with SLC2A9 variants in the Swedish Obese Subjects Study
|OA=1
}}

{{PMID Auto
|PMID=24379826
|Title=Genome-wide association analysis confirms and extends the association of SLC2A9 with serum uric acid levels to Mexican Americans
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}